[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2524091A1 - Pharmaceutical formulation of the telmisartan sodium salt - Google Patents

Pharmaceutical formulation of the telmisartan sodium salt Download PDF

Info

Publication number
CA2524091A1
CA2524091A1 CA002524091A CA2524091A CA2524091A1 CA 2524091 A1 CA2524091 A1 CA 2524091A1 CA 002524091 A CA002524091 A CA 002524091A CA 2524091 A CA2524091 A CA 2524091A CA 2524091 A1 CA2524091 A1 CA 2524091A1
Authority
CA
Canada
Prior art keywords
composition according
sodium salt
water
telmisartan
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002524091A
Other languages
French (fr)
Other versions
CA2524091C (en
Inventor
Anja Kohlrausch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2524091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2524091A1 publication Critical patent/CA2524091A1/en
Application granted granted Critical
Publication of CA2524091C publication Critical patent/CA2524091C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to a medicament formulation of the crystalline sodium salt of 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (Telmisartan) and methods for production thereof.

Claims (14)

1. Pharmaceutical composition containing the telmisartan sodium salt and a diuretic.
2. The composition according to claim 1 containing one or more formulation excipients selected from among mannitol, sorbitol, xylitol, saccharose, calcium carbonate, calcium phosphate, lactose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose, maize starch, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose or starch, magnesium stearate, sodium stearylfumarate, talc, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, polyvinyl acetate, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof.
3. Pharmaceutical composition containing the telmisartan sodium salt, optionally a diuretic, and one or more formulation excipients selected from among sorbitol, xylitol, saccharose, croscarmellose sodium salt, crospovidone, sodium starch glycolate, hydroxypropylcellulose, polyvinylpyrrolidone, copolymers of vinylpyrrolidone with other vinyl derivatives (copovidone), hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline cellulose or sodium stearylfumarate, hydroxypropylmethylcellulose, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetylstearylalcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof.
4. The composition according to claims 1 to 3 containing the diuretic hydrochlorothiazide (HCTZ).
5. The composition according to claims 1 to 3, characterised in that the hydrochlorothiazide is present in an amount of 10-15 mg or 20-30 mg.
6. The composition according to claims 1 to 3, characterised in that the sodium salt of telmisartan is present in an amount of 60-90 mg.
7. The composition according to claim 8, characterised in that the sodium salt of telmisartan is present in an amount of 80-85 mg.
8. The composition according to claims 1 to 3, characterised in that the sodium salt of telmisartan is present in an amount of 30-60 mg.
9. The composition according to claim 8, characterised in that the sodium salt of telmisartan is present in an amount of 40-45 mg.
10. The composition according to claims 7 and 9, characterised in that hydrochlorothiazide is present in an amount of 12-13 mg or 24-26 mg.
11. The composition according to claim 1, characterised in that the active substances is present together with the excipients sorbitol and magnesium stearate, compressed directly into tablets.
12. The composition according to claim 1, characterised in that the active substances are present as compressed dry granules of the telmisartan sodium salt containing the excipients mannitol, magnesium stearate and hydroxypropylcellulose with a mixture of hydrochlorothiazide, mannitol, microcrystalline cellulose and sodium glycol starch.
13. The composition according to claim 1, characterised in that the telmisartan sodium salt is formulated with additional pharmaceutically active substances.
14. Process for preparing the pharmaceutical composition according to claims 1 to 3, characterised in that the active substances are compressed with the excipients to form tablets.
CA2524091A 2003-04-30 2004-04-27 Pharmaceutical formulation of the telmisartan sodium salt Expired - Fee Related CA2524091C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10319450A DE10319450A1 (en) 2003-04-30 2003-04-30 Pharmaceutical formulation of telmisartan sodium salt
DE10319450.9 2003-04-30
PCT/EP2004/004425 WO2004096215A1 (en) 2003-04-30 2004-04-27 Pharmaceutical formulation of the sodium salt of telmisartan

Publications (2)

Publication Number Publication Date
CA2524091A1 true CA2524091A1 (en) 2004-11-11
CA2524091C CA2524091C (en) 2012-02-21

Family

ID=33305059

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2524091A Expired - Fee Related CA2524091C (en) 2003-04-30 2004-04-27 Pharmaceutical formulation of the telmisartan sodium salt

Country Status (22)

Country Link
EP (1) EP1622612B9 (en)
JP (2) JP5156231B2 (en)
KR (1) KR20060008943A (en)
CN (1) CN100589802C (en)
AR (2) AR044142A1 (en)
AT (1) ATE388703T1 (en)
AU (1) AU2004233581B2 (en)
BR (1) BRPI0409809A (en)
CA (1) CA2524091C (en)
CL (1) CL2004000899A1 (en)
DE (2) DE10319450A1 (en)
DK (1) DK1622612T3 (en)
ES (1) ES2303634T4 (en)
IL (1) IL171465A (en)
MX (1) MXPA05011647A (en)
NZ (1) NZ543775A (en)
PE (1) PE20050464A1 (en)
RU (1) RU2372918C2 (en)
TW (1) TWI364278B (en)
UY (1) UY28293A1 (en)
WO (1) WO2004096215A1 (en)
ZA (1) ZA200507223B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044754A3 (en) * 2004-10-18 2006-12-14 Reddys Lab Ltd Dr Process for preparing telmisartan
WO2011147026A2 (en) * 2010-05-28 2011-12-01 Pharmascience, Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
DE10319592A1 (en) * 2003-05-02 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment of diabetic retinopathy with angiotensin II receptor blockers
SI2269583T1 (en) 2006-06-16 2014-12-31 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
TWI482772B (en) 2006-08-21 2015-05-01 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo(4,5-d)pyrimidin derivate
WO2009058950A2 (en) * 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
CZ301299B6 (en) 2008-11-24 2010-01-06 Zentiva, A.S. Solid pharmaceutical composition with atorvastatin and telmisartan active ingredients
SI2443094T1 (en) 2009-06-19 2013-08-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
EP2448575A2 (en) * 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
JP2011136908A (en) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk Solid preparation including angiotensin ii receptor antagonist and method of improving storage stability of angiotensin ii receptor antagonist in the solid preparation
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
PT2640371T (en) * 2010-11-15 2020-04-17 Boehringer Ingelheim Int Vasoprotective and cardioprotective antidiabetic therapy
US9446032B2 (en) * 2011-08-26 2016-09-20 Wockhardt Limited Methods for treating cardiovascular disorders
CN102526037B (en) * 2012-02-10 2014-08-27 重庆康刻尔制药有限公司 Telmisartan medicinal composition, telmisartan medicinal composition tablets and preparation method for telmisartan medicinal composition tablets
EP2649996A1 (en) * 2012-04-11 2013-10-16 Laboratorios Del. Dr. Esteve, S.A. Crystalline forms of sartans like telmisartan with beta blockers
JP6018420B2 (en) * 2012-06-05 2016-11-02 ニプロ株式会社 Pharmaceutical composition comprising an angiotensin II receptor antagonist and thiazide diuretic
JP6428340B2 (en) * 2014-05-23 2018-11-28 ニプロ株式会社 Method for granulating a pharmaceutical composition comprising telmisartan
JP5956034B1 (en) * 2015-07-27 2016-07-20 エルメッド エーザイ株式会社 Telmisartan-containing pharmaceutical composition
CN107501192A (en) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 The eutectic of Telmisartan and Hydrochioro
KR20200043618A (en) * 2018-10-18 2020-04-28 주식회사유한양행 Pharmaceutical composition for oral administration comprising an aminopyrimidine derivative or its salt

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
JP4107831B2 (en) * 2000-11-21 2008-06-25 第一三共株式会社 Pharmaceutical composition
US20040242891A1 (en) * 2001-10-26 2004-12-02 Jonathan Campbell Production of keto acids
DE10153737A1 (en) * 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
EA007614B1 (en) * 2002-01-16 2006-12-29 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Bilayer pharmaceutical tablet and method for producing thereof
DE10244681A1 (en) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh New solid telmisartan-containing pharmaceutical formulations and their preparation
DE10301371A1 (en) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment or prophylaxis of cardiovascular, cardiopulmonary or renal diseases, e.g. hypertension combined with hyperlipidemia or atherosclerosis, using combination of telmisartan and atorvastatin
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044754A3 (en) * 2004-10-18 2006-12-14 Reddys Lab Ltd Dr Process for preparing telmisartan
US7943781B2 (en) 2004-10-18 2011-05-17 Dr. Reddy's Laboratories Limited Process for preparing telmisartan
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
WO2011147026A2 (en) * 2010-05-28 2011-12-01 Pharmascience, Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
WO2011147026A3 (en) * 2010-05-28 2012-01-26 Pharmascience, Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide

Also Published As

Publication number Publication date
MXPA05011647A (en) 2005-12-15
DE10319450A1 (en) 2004-11-18
JP2010138207A (en) 2010-06-24
JP5156231B2 (en) 2013-03-06
EP1622612B9 (en) 2008-11-05
ES2303634T3 (en) 2008-08-16
ATE388703T1 (en) 2008-03-15
ES2303634T4 (en) 2009-04-01
CL2004000899A1 (en) 2005-03-04
WO2004096215A1 (en) 2004-11-11
CN1780618A (en) 2006-05-31
TWI364278B (en) 2012-05-21
UY28293A1 (en) 2004-11-30
TW200509914A (en) 2005-03-16
JP2006524635A (en) 2006-11-02
ZA200507223B (en) 2006-05-31
RU2005137031A (en) 2007-06-10
DK1622612T3 (en) 2008-05-26
AR044142A1 (en) 2005-08-24
CN100589802C (en) 2010-02-17
AU2004233581B2 (en) 2010-04-22
KR20060008943A (en) 2006-01-27
RU2372918C2 (en) 2009-11-20
BRPI0409809A (en) 2006-05-09
EP1622612B1 (en) 2008-03-12
AR087210A2 (en) 2014-02-26
DE502004006500D1 (en) 2008-04-24
NZ543775A (en) 2009-03-31
IL171465A (en) 2010-06-30
EP1622612A1 (en) 2006-02-08
AU2004233581A1 (en) 2004-11-11
CA2524091C (en) 2012-02-21
JP5254268B2 (en) 2013-08-07
PE20050464A1 (en) 2005-07-04

Similar Documents

Publication Publication Date Title
CA2524091A1 (en) Pharmaceutical formulation of the telmisartan sodium salt
US6677342B2 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US5948437A (en) Pharmaceutical compositions using thiazepine
CA2251944C (en) Sustained release pharmaceutical compositions comprising a dibenzothiazepine derivative
AU2007297333B2 (en) Solid dosage form of olmesartan medoxomil and amlodipine
US8785432B2 (en) Pharmaceutical compositions of amlodipine and valsartan
US11819577B2 (en) Fixed dose pharmaceutical composition of valsartan and sacubitril
EA021317B1 (en) Monolayer tablets comprising irbesartan and amlodipine, their preparation and their therapeutic application
WO2014030051A1 (en) Stable pharmaceutical compositions comprising saxagliptin
KR20190015329A (en) A pharmaceutical composition of a dapagliflozin co-crystal
US20080008751A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
US20080227836A1 (en) Stable Solid Oral Dosage Forms of Valsartan
WO2007049868A1 (en) Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
WO2007049291A1 (en) Novel solid dosage forms of valsartan and rochlorothiazide
WO2020106020A1 (en) Bilayer tablet and preparation method therefor
KR20090065510A (en) Solid dosage form of olmesartan medoxomil and amlodipine
EP1889629B1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
JPH0820537A (en) Solid preparation containing antiulcer agent
KR100484994B1 (en) Pharmacy Composition
KR20120090401A (en) Compositions for controlled release formulation containing zaltoprofen and process for the preparation thereof
WO2017119629A1 (en) Pharmaceutical composition comprising nebivolol with improved dissolution rate
CN112263581A (en) Double-layer tablet compound preparation for treating PE and ED and preparation method thereof
CA2659814A1 (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
GB2471970A (en) Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide
KR20090021222A (en) Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160427